Article Text

Download PDFPDF

OP0062 Assessment of biotherapies' efficacy in blau syndrome: data from an international retrospective cohort of 23 cases
  1. O Fogel1,
  2. A Cantagrel2,
  3. K Ikeda3,
  4. P Sève4,
  5. E Hachulla5,
  6. R Cimaz6,
  7. P Sfriso7,
  8. L Punzi7,
  9. C Pajot8,
  10. E Grouteau8,
  11. S Tellier8,
  12. C Galeotti9,
  13. S Grotto10,
  14. J Sibilia11,
  15. B Bodaghi12,
  16. I Touitou13,
  17. C Miceli-Richard1
  1. 1Hopital Cochin, paris
  2. 2Hôpital Purpan, Toulouse, France
  3. 3Chiba University Hospital, Chiba, Japan
  4. 4Hopital de la Croix Rousse, Lyon
  5. 5CHRU Lille, Lille, France
  6. 6Anna Meyer Children's Hospital, Florence
  7. 7University of Padova, Padova, Italy
  8. 8Hopital des Enfants, Toulouse
  9. 9CHU Bicetre, le Kremlin Bicetre
  10. 10CHU Rouen, Rouen
  11. 11CHRU Strasbourg, Strasbourg
  12. 12CHU pitié Salpetriere, Paris
  13. 13CHU Montpellier, Montpellier, France


Background Blau Syndrome (BS) is a rare autosomal dominant inflammatory disease characterized by early-onset granulomatous arthritis, dermatitis and recurrent uveitis (1). Mutations in the nucleotide-binding domain (NBD) of CARD15/NOD2 gene (mainly R334W, R334Q and L469F) have been identified in Blau syndrome (2). Despite advances in BS knowledge, patients' functional prognosis remains uncertain, BS potentially leading to visual impairment or joint deformities. Optimal treatments have not been determinated yet.

Objectives To assess the efficacy of several biologic agents in this affection

Methods We conduct an observational, international, retrospective cohort of BS collecting clinical, biological and histological data.

Results Among the twenty-three patients included in the cohort, 14 patients were treated by one or several lines of biologic agents, mostly by TNF blockers (80%), IL1 blockers (16%) or treatment targeting CTLA-4 (4%). Fifty-seven percent of patients achieved remission after almost two lines of treatment (1.75 lines; [0.8–2.7]). Association with csDMARDs did not significantly improved response to biologics. Considering the 3 mains symptoms independently, TNF blockers were associated with a better response in case of articular or skin features but less effective in case of ocular involvement, a clinical situation in which IL-1 targeting should be preferentially chosen.

Conclusions Biologic treatments appeared to be effective in BS but additional data prospectively collected are still needed in order to define their place in the therapeutic strategy in order to minimize functional consequences.


  1. Blau EB. Familial granulomatous arthritis, iritis, and rash. The Journal of pediatrics. 1985 Nov;107(5):689–93. PubMed PMID: 4056967. Epub 1985/11/01. eng.

  2. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, et al. CARD15 mutations in Blau syndrome. Nature genetics. 2001 Sep;29(1):19–20. PubMed PMID: 11528384. Epub 2001/08/31. eng.


Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.